Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,462 total articles
Grab’s $1.49B purchase of a majority stake in Atome, combined with accelerating Financial Services growth, sets a plausible runway toward meaningfully higher adjusted EBITDA. The market has punished GRAB on execution and capital concerns; this trade buys a disciplined dip with a 180-trading-day horizon, tight stop and a target that prices in partia…
Coca-Cola combines predictable free cash flow, industry-leading margins and a 2.4%+ yield with steady volume recovery. At $88.04, KO trades at a premium versus peers, but superior ROE, solid free cash flow of $14.3B and a durable global footprint make it a high-conviction long-term trade. Entry at $88.04, target $100, stop $81 for a 180-trading-day…
Enact Holdings (ACT) looks actionable on a mid-term long after a modest pullback: strong cash generation, low leverage, a large $500M buyback and a bumped quarterly dividend provide near-term support while P/E and free cash flow metrics leave room for upside if underwriting trends remain stable.
Oceaneering (OII) pairs a diversified offshore services portfolio with rapidly growing Subsea Robotics demand. At $45.06 the stock offers exposure to secular offshore capex, attractive cash flow generation ($223.2M FCF), and a reasonable valuation (P/E ~12.8, EV/EBITDA ~10.6). This trade idea outlines an actionable mid-term long with entry, stop an…
Palantir is trading near $203 with a market cap of roughly $488B and a mix of hyper-growth and software margins that could support a $1T valuation if execution and ARR expansion continue. This trade idea lays out a long entry at $203.10, a stop at $170.00 and a target of $416.15 over a 180 trading day horizon, with catalysts, valuation framing and …
Harmonic Drive Systems (HSYDF) is an OTC-listed precision components company that looks set for a long recovery run. Price action at $40.88 is breaking near-term resistance after a low-volume base, technical indicators are mixed but improving, and short interest readings show an unusually stretched bear book - a setup that can amplify rallies if fu…
Micron is the primary beneficiary of an AI-led memory supercycle. Strong DRAM revenue, record free cash flow and tight industry supply create a compelling risk/reward for a mid-term long. This trade idea lays out an entry, stop and target with catalysts and a clear plan for reassessment.
Dollar General's brick-and-mortar scale, steady free cash flow ($2.01B) and modest valuation (market cap ~$27.5B; P/E ~16) make it an attractive long if an Instacart partnership meaningfully accelerates digital sales and fulfillment efficiency. We lay out a long trade with entry, stop and target, balanced catalysts, and explicit risks.
Ally Financial (ALLY) is trading at roughly $37.63, a valuation that implies the market is pricing it below book and likely below tangible book. With a market cap near $11.45B, EPS around $4.37, a P/E under 9x, and meaningful free cash flow generation, the risk/reward favors a long swing trade as high-cost deposits roll off and net interest margin …
argenx stock has been punished in recent sessions amid Sjögren's noise and profit-taking, leaving the shares trading well below near-term moving averages and with an RSI of 23.6. With a $51.19B market cap, expanding ENHANZE collaboration, a completed acquisition that broadens the pipeline, and supportive real-world data for VYVGART, the setup looks…
lululemon trades like a distressed growth stock but still produces strong cash and returns; at a $10.7B market cap the company’s free cash flow and low multiples offer a 43% upside to $132.30 even under a prolonged Americas slowdown. This trade pairs a disciplined entry and stop with a long-term horizon to ride a valuation re-rating or a fundamenta…
UnitedHealth (UNH) typically outperforms on execution and guidance. The market appears to have baked in a near-term beat; that makes the trade conditional, not reckless. With a clear entry at $600.00, stop at $570.00 and a target of $660.00 over a mid-term (45 trading days) horizon, this is a risk-defined, event-driven long that aims to capture ups…
Broadcom ($AVGO) is trading on concern over Anthropic's $518B cloud plans and the ripple effects on hyperscaler spending. Those fears are real but overstated for Broadcom. The company sits on high-margin AI networking assets and strong free cash flow. We view the sell-off as a tactical entry: buy on weakness with a mid-term target of $420 and a str…
Nano Labs (NA) is a micro-cap fabless chip designer that reported severe H1 2026 pain but retains a strategic crypto reserve and a product pipeline targeting AI and Web3 convergence. At a $48M market cap and $2.19 stock price, the risk-reward is asymmetric if upcoming operational updates and product rollouts show traction. This is a high-risk, cata…
Adobe’s current valuation implies a very low growth trajectory through FY2030. With $10.6B in free cash flow, $24.55B of buyback capacity and AI-driven product upgrades in Creative Cloud and Experience Cloud, the risk-reward favors a long trade. Entry $242.65, target $300.00, stop $215.00; horizon: long term (180 trading days).
ConnectOne Bancorp (CNOB) looks attractively priced at roughly $1.5B market cap with P/E ~9.9 and P/B ~0.93. The merger with The First of Long Island and solid free cash flow provide clear catalysts; commercial real estate exposure and macro sensitivity keep this a medium-risk tactical long over the next 45 trading days.
AppLovin has been punished for an incomplete AI product rollout and litigation headlines, but the underlying business still generates substantial free cash flow, posted double-digit EPS, and is trading well below prior highs. I upgrade to Buy on a tactical pullback with a mid-term trade plan and strict risk controls.
Tesla remains a growth story: high revenue momentum, improving technicals, and strong free cash flow support a mid-term long. But management’s large-capex ambitions (reports of roughly $25B) and steep valuation mean this is a trade to size and manage with a disciplined stop. Entry $380.00, target $430.00, stop $345.00, mid-term horizon (45 trading …
Advanced Micro Devices has the product cycle and customer momentum to drive meaningful gross- and operating-margin expansion. The market's recent volatility and short-term focus create an asymmetric trade: buy on weakness with a tight stop and a mid-term horizon as margin beats and contract renewals flow through the P&L.
State Street (STT) looks attractively positioned as a high-quality, institutional-services bank with a clean balance sheet, recurring revenue streams, and a modest valuation. With consensus expecting a strong Q3 report and the stock trading well below key moving averages, we prefer a tactical long into a mid-term horizon to capture potential earnin…
Broadcom's share-price pullback has more to do with confused headlines than fundamentals. The company sits at the center of AI infrastructure - networking silicon, high-speed NICs, and software - and should be a primary beneficiary as cloud and model-builders scale capacity. Given strong free cash flow, a manageable balance sheet, recent product an…
Eli Lilly's cardiometabolic franchise continues to dominate industry headlines and company sales. The stock has pulled back from highs but fundamentals and technicals suggest the recent dip is a buying opportunity for a measured 180-day trade. Trade plan, rationale, catalysts, and balanced risks provided.
After a transformational asset sale earlier this year the market is effectively pricing Vistance's remaining networking and access businesses at roughly 2.5x EV/EBITDA and under 0.6x sales. With zero reported debt, a strong current ratio and recent special distributions, VISN looks like a tactical long around current levels. This trade idea lays ou…
I am upgrading Pfizer (PFE) from bearish to a cautious bullish stance. The stock offers a mix of reliable free cash flow ($10.99B), a rich dividend yield (~6.14%), and accelerating oncology revenues that should support multiple expansion. This is a trade idea for investors willing to accept company- and sector-specific regulatory risk in exchange f…
The Elmet Group is uniquely positioned as a U.S.-centric tungsten and precision components supplier with direct Department of Defense backing, a freshly solidified supply line via Masan, and a tight float that can amplify upside. We initiate a position with clear entry, stop and target levels and a plan that spans from tactical to position-sized ho…
